

PONVORY™
(ponesimod tablets)

PREGNANCY REMINDER CARD

Information for female patients of childbearing potential



BEFORE STARTING PONVORY™

- PONVORY™ is used to treat adults with relapsing remitting Multiple Sclerosis (RRMS).
- PONVORY™ must not be used during pregnancy or by women of childbearing potential not using highly effective contraception. PONVORY™ may harm your unborn baby.
- Your doctor should perform a pregnancy test to confirm that you are not pregnant **before** you start treatment with PONVORY™.
- Do not use PONVORY™ if you are of childbearing age and not using an effective method of birth control. Women of childbearing potential should be counseled on the potential for a serious risk to the fetus and the need for highly effective contraception during treatment with PONVORY™.
- You should not use PONVORY™ if you are pregnant, think you may be pregnant or plan to get pregnant.
- If you are breastfeeding or planning to breast-feed your baby, inform your doctor and discuss continuing your treatment or other treatment options as PONVORY™ as a risk to newborns/infants cannot be excluded.
- Consult your doctor about effective contraception you should use throughout therapy and for at least 2 weeks after stopping PONVORY® medication.

DURING TREATMENT WITH PONVORY™

- **You must not become pregnant while taking PONVORY™.** A pregnancy test should be repeated at suitable times during PONVORY® treatment.
- **If you become pregnant while taking PONVORY™, stop taking it and tell your doctor right away.** PONVORY™ may harm your unborn baby.
- If you are of childbearing potential, and you might get pregnant, you should use effective birth control methods during treatment and for at least **1 week** after stopping PONVORY™. Ask your doctor about options of effective birth control.
- If you suspect pregnancy or decide to become pregnant, you should tell your doctor straight away.
- You should not breastfeed while taking PONVORY®.

For further information, please contact Juvisé Pharmaceuticals:
Email: ponvoryeducationalmaterial@juvise.com.

AFTER STOPPING PONVORY™ TREATMENT

You must not become pregnant for at least 1 week after you stop taking PONVORY™. If you become pregnant while taking PONVORY™, stop taking it and tell your doctor right away. PONVORY™ may harm your unborn baby.

If you stop taking PONVORY® because you are pregnant or trying to get pregnant, your multiple sclerosis symptoms may come back, grow worse, or develop new symptoms. If you feel this after stopping your PONVORY® treatment, consult your doctor right away.



Adverse events reporting guidance:

SFDA (National Pharmacovigilance center)

Email: npc.drug@sfd.a.gov.sa

Telephone: 19999

Online: <http://ade.sfd.a.gov.sa>

For full prescribing information, please refer to the datasheet or contact

Cigalah Healthcare Company

Address: ottoman bin affan street, Almamoun building, Ground floor, Pharmacovigilance Department

Office Tel +966-12-6148000

Postal address: P O Box 19435 Jeddah 21435, Saudi Arabia

To report Adverse Events/Product Complaint or any Medical Information Inquiries, please contact us at:

Email: Drug-Safety@Cigalah.com.sa

Hotline: +966-539455825



This risk minimization activity has been reviewed and approved by the Saudi FDA
Version 2.0, 03/2026, AR-PI-00925-1

